SMS Lifesciences India has received establishment inspection report (EIR) with a voluntary action indicated (VAI) status from the U.S. Food and Drug Administration (USFDA) for its API manufacturing facility (Unit 1) located at Kazipally, Telangana, on July 15, 2025. The receipt of EIR reaffirms the company’s commitment to maintaining global quality standards and enables access to the regulated US market and other highly regulated global markets.
SMS Lifesciences India is presently engaged in the business of manufacturing, buying, selling, offering consultancy, importing and exporting, acting as commission agents and generally dealing with of all types of Organic & Inorganic Chemicals, Pharmaceuticals, API and Intermediates.
